Back
Ultragenyx Pharmaceutical, Inc. 10K Form
Sell
25
RARE
Ultragenyx Pharmaceutical, Inc.
Last Price:
$22.73
Seasonality Move:
-1.26%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-03 | 10Q | RARE/Ultragenyx Pharmaceutical, Inc. Quarterly |
| 2023-11-03 | 10Q | RARE/Ultragenyx Pharmaceutical, Inc. Quarterly |
| 2023-08-04 | 10Q | RARE/Ultragenyx Pharmaceutical, Inc. Quarterly |
| 2023-05-05 | 10Q | RARE/Ultragenyx Pharmaceutical, Inc. Quarterly |
| 2022-11-03 | 10Q | RARE/Ultragenyx Pharmaceutical, Inc. Quarterly |
| 2022-07-29 | 10Q | RARE/Ultragenyx Pharmaceutical, Inc. Quarterly |
Receive RARE News And Ratings
See the #1 stock for the next 7 days that we like better than RARE
RARE Financial Statistics
Sales & Book Value
| Annual Sales: | $673M |
|---|---|
| Cash Flow: | $-100.8M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-0.83 |
| Price / Book: | 215.41 |
Profitability
| EPS (TTM): | -5.83610 |
|---|---|
| Net Income (TTM): | $-575.4M |
| Gross Margin: | $537M |
| Return on Equity: | -558.7% |
| Return on Assets: | -42.04% |
Ultragenyx Pharmaceutical, Inc. Earnings Forecast
Key Ultragenyx Pharmaceutical, Inc. Financial Ratios
-
The Gross Profit Margin over the past 22 years for RARE is 79.79%.
-
The Selling, General & Administrative Expenses for RARE have been equal to 51.86% of Gross Profit Margin.
-
The Research & Development expenses have been 107.43% of Revenue.
-
The Net Earning history of RARE is -85.44% of Total Revenues.
-
Per Share Earnings over the last 22 years have been positive in 10 years.
Ultragenyx Pharmaceutical, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | RARE |
| CUSIP: | 90400D |
| Website: | ultragenyx.com |
Debt
| Debt-to-Equity Ratio: | -15.65 |
|---|---|
| Current Ratio: | 2.48 |
| Quick Ratio: | 2.22 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 275.39 |
RARE Technical Analysis vs Fundamental Analysis
Sell
25
Ultragenyx Pharmaceutical, Inc. (RARE)
is a Sell
Is Ultragenyx Pharmaceutical, Inc. a Buy or a Sell?
-
Ultragenyx Pharmaceutical, Inc. stock is rated a SellThe current Ultragenyx Pharmaceutical, Inc. [RARE] share price is $21.83. The Score for RARE is 25, which is 50% below its historic median score of 50, and infers higher risk than normal.